These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2957985)

  • 1. Plasma prolactin and dehydroepiandrosterone sulfate levels in polycystic ovarian disease.
    Lee JY; Yoon BK; Moon SY; Kim JG; Chang YS
    Asia Oceania J Obstet Gynaecol; 1987 Jun; 13(2):215-20. PubMed ID: 2957985
    [No Abstract]   [Full Text] [Related]  

  • 2. [Relation between prolactin and dehydroepiandrosterone sulfate in women with polycystic ovary disease].
    Bruno B; Poccia G; Masci A
    Minerva Endocrinol; 1985; 10(4):223-7. PubMed ID: 2939335
    [No Abstract]   [Full Text] [Related]  

  • 3. [Polycystic ovary syndrome with excess of prolactin].
    Ataniiazova OA; Orlova VG; Smetnik VP; Afonina LI
    Akush Ginekol (Mosk); 1990 Apr; (4):42-4. PubMed ID: 2143054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A
    J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma dehydroepiandrosterone sulfate and other androgens in normo- and hyperprolactinemic women with polycystic ovary disease.
    Teter J; Kwiatkowska Z; Kwiatkowska E
    Endokrynol Pol; 1983; 34(4):219-26. PubMed ID: 6228419
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.
    Lewinthal D; Corenblum B; Taylor PJ
    Int J Fertil; 1987; 32(3):185-7, 191. PubMed ID: 2885281
    [No Abstract]   [Full Text] [Related]  

  • 7. A controlled clinical trial for the effect of bromocriptine on the adrenal contribution in polycystic ovarian disease.
    el Tabbakh GH; Loutfi IA; Azab I; Rahman HA; Aleem FA; Southren AL
    Acta Endocrinol (Copenh); 1987 Feb; 114(2):161-5. PubMed ID: 2950709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unusual case of Cushing's syndrome, hilus cell tumor and polycystic ovaries.
    Korth-Schutz S; Levine LS; Merkatz IR; New MI
    J Clin Endocrinol Metab; 1974 May; 38(5):794-800. PubMed ID: 4363071
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
    Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
    Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprolactinemia and polycystic ovarian syndrome.
    Tzingounis VA; Aksu MF; Tsoukalos SG
    Int J Fertil; 1979; 24(4):276-80. PubMed ID: 45100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin secretion in polycystic ovary syndrome: circadian rhythmicity and dynamic aspects.
    Ferrari E; Bossolo PA; Foppa S; Dalzano M; Comis S; Morelli MP; Peveri V; Mengozzi A
    Gynecol Endocrinol; 1988 Jun; 2(2):101-11. PubMed ID: 3188970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of ultrasonically diagnosed polycystic ovaries. II. Studies of dynamic and pulsatile hormonal patterns.
    Abdel Gadir A; Khatim MS; Mowafi RS; Alnaser HM; Muharib NS; Shaw RW
    Hum Reprod; 1992 Apr; 7(4):458-61. PubMed ID: 1387880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polycystic ovary syndrome associated with remarkable hyperprolactinemia--case report].
    Owecki M; Sowiński J
    Pol Merkur Lekarski; 2004 Oct; 17(100):385-7. PubMed ID: 15690710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinemia after laparoscopic ovarian drilling: an unknown phenomenon.
    Parsanezhad ME; Alborzi S; Zolghadri J; Parsa-Nezhad M; Keshavarzi G; Omrani GR; Schmidt EH
    Reprod Biol Endocrinol; 2005 Aug; 3():31. PubMed ID: 16083511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dehydroepiandrosterone sulfate in the differential diagnosis of adrenal and ovarian dysfunction in women with hirsutism and anovulation].
    Divila F; Presl J; Stroufová A
    Cesk Gynekol; 1986 Apr; 51(3):160-6. PubMed ID: 2941167
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of and markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease.
    Benjamin F; Deutsch S; Saperstein H; Seltzer VL
    Fertil Steril; 1986 Aug; 46(2):215-21. PubMed ID: 3015693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prolactin levels in women with polycystic ovary syndrome after treatment with clomiphene].
    Milewicz A; Szymczak J; Tupikowska G; Grabiński M
    Ginekol Pol; 1985 Mar; 56(3):132-7. PubMed ID: 4054664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.